The trial will be held at 7 NHS sites in the U.K. with the NIHR funding 66% of the cost The post Awakn set to research...
Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6, WKN: A3CSSU) the Company is pleased to announce that its wholly-owned subsidiary, Vocan...
Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman...
The article Mydecine Closes Sale of Mindleap for $3.6 million was originally published on Microdose. Starting this summer, we began reporting on the apparent...
The company filed provisional patents for the use of psilocybin to treat binge eating disorder and fibromyalgia. The post Tryp’s Clinical Psychedelics...
Psychedelics were once thought to provide fun trips and little else. Now, we know that psychedelics have the potential to provide a variety of benefits....
Source: Streetwise Reports 12/12/2022 Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment...
The article Awakn’s Phase 3 Trial Launching With UK National Health Service was originally published on Microdose. Awakn Life Sciences has announced...
Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing...
Filament Health (OTCQB:FLHLF | NEO:FH | FSE:7QS), a clinical stage natural psychedelic drug development company, today announced that Benjamin Lightburn,...